-
2023-510155-37-00
5
2025-05-08
Hypomethylating agent (HMA) naive myelodysplastic syndromes
Myelodyspl
-
2023-506512-40-00
5
2025-04-16
Acute Kidney Injury
-
2023-506601-19-00
6
2025-04-15
transplantation
-
2024-516791-15-00
4
2025-04-08
Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
-
2023-504086-23-00
5
2025-03-27
Subjects with PBC with a non-optimal response to UDCA.
-
2024-514804-14-00
6
2025-03-26
Liver transplantation
-
2023-508201-25-00
4
2025-03-12
Hepatocellular carcinoma
-
2023-508798-94-00
5
2025-02-11
Heart failure
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-510772-20-00
4
2025-02-06
Rectal cancer locally advanced with microsatellite unstable or mismatc
-
2024-513853-66-00
5
2025-02-04
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
-
2023-509146-35-00
6
2025-01-30
Systemic Lupus Erythematosus
-
2024-513852-13-00
5
2025-01-20
KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
-
2023-509963-25-00
4
2025-01-17
Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer
-
2023-510507-21-00
10
2025-01-08
Intersitial lung disease related to systemic sclerosis
-
2024-511099-34-00
1
2024-12-12
B-Cell Malignancies
-
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)
-
2024-516109-21-00
5
2024-12-09
Polycythaemia Vera (PV)
-
2023-508949-40-00
4
2024-11-29
Eosinophilic esophagitis
-
2024-514331-24-00
4
2024-11-22
Prosthetic valve infective endocarditis
-
2024-513009-30-00
4
2024-11-21
Moderate to Severe Crohn’s Disease
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2023-505232-36-00
5
2024-11-15
Essential thrombocythemia